CG Oncology Inc (CGON) is now in the Overvalued zone, suggesting that its current forward PS ratio of 4209.06 is considered Overvalued compared with the five-year average of -17.70. The fair price of CG Oncology Inc (CGON) is between 26.56 to 53.56 according to relative valuation method. Compared to the current price of 58.85 USD , CG Oncology Inc By Overvalued By 9.88%.

Relative Value

Fair Zone

26.56-53.56

Current Price：58.85

9.88%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is CG Oncology Inc (CGON) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

CG Oncology Inc (CGON) has a current Price-to-Book (P/B) ratio of 4.76. Compared to its 3-year average P/B ratio of 3.27, the current P/B ratio is approximately 45.45% higher. Relative to its 5-year average P/B ratio of 3.27, the current P/B ratio is about 45.45% higher. CG Oncology Inc (CGON) has a Forward Free Cash Flow (FCF) yield of approximately -3.47%. Compared to its 3-year average FCF yield of -3.32%, the current FCF yield is approximately 4.66% lower. Relative to its 5-year average FCF yield of -3.32%, the current FCF yield is about 4.66% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for CGON competitors is 762.99, providing a benchmark for relative valuation. CG Oncology Inc Corp (CGON.O) exhibits a P/S ratio of 4209.06, which is 451.65% above the industry average. Given its robust revenue growth of 409.21%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of CGON increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of CGON in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is CGON currently overvalued or undervalued?

What is CG Oncology Inc (CGON) fair value?

CGON's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of CG Oncology Inc (CGON) is between 26.56 to 53.56 according to relative valuation method.

How does CGON's valuation metrics compare to the industry average?

The average P/S ratio for CGON's competitors is 762.99, providing a benchmark for relative valuation. CG Oncology Inc Corp (CGON) exhibits a P/S ratio of 4209.06, which is 451.65% above the industry average. Given its robust revenue growth of 409.21%, this premium appears sustainable.

What is the current P/B ratio for CG Oncology Inc (CGON) as of Mar 02 2026?

As of Mar 02 2026, CG Oncology Inc (CGON) has a P/B ratio of 4.76. This indicates that the market values CGON at 4.76 times its book value.

What is the current FCF Yield for CG Oncology Inc (CGON) as of Mar 02 2026?

As of Mar 02 2026, CG Oncology Inc (CGON) has a FCF Yield of -3.47%. This means that for every dollar of CG Oncology Inc's market capitalization, the company generates -3.47 cents in free cash flow.

What is the current Forward P/E ratio for CG Oncology Inc (CGON) as of Mar 02 2026?

As of Mar 02 2026, CG Oncology Inc (CGON) has a Forward P/E ratio of -15.37. This means the market is willing to pay $-15.37 for every dollar of CG Oncology Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for CG Oncology Inc (CGON) as of Mar 02 2026?

As of Mar 02 2026, CG Oncology Inc (CGON) has a Forward P/S ratio of 4209.06. This means the market is valuing CGON at $4209.06 for every dollar of expected revenue over the next 12 months.

CGON Valuation